ACHA Webinars Presents:

Pulmonary Arterial Hypertension in Adult Congenital Heart Disease: What’s New on the Horizon?

Wednesday, October 14, 2015, 7 p.m. – 8 p.m. EDT

Presenter:
Michael Earing, MD

About the Webinar
Did you know that the numbers of adults with congenital heart disease (CHD) who have developed pulmonary arterial hypertension (PAH) or high blood pressure in their lungs is growing? Join us to hear Dr. Michael Earing, noted ACHD cardiologist, review the causes of PAH, how common it is, what complications might occur, and treatment options. Register today for more information on these topics and to learn how to improve the quality of your life. You don’t want to miss this webinar.

REGISTER NOW:
https://attendee.gotowebinar.com/register/1250481540444483841

About the Presenter
Dr. Earing received his Doctor of Medicine degree from Rush Medical College in Chicago. He completed a combined pediatrics and internal medicine residency at Rush University Medical Center in Chicago, where he won the Outstanding Senior Resident and Outstanding Resident Teacher awards, as well as the Center’s Hero of the Heart Award. He completed his adult congenital heart disease training at the Mayo Clinic in Rochester, MN, where he won the American Academy of Pediatrics Young Clinical Investigator of the Year Award. He is currently the Director of the Wisconsin Adult Congenital Heart Disease Program (WAtCH) and Professor of Internal Medicine and Pediatrics at the Medical College of Wisconsin in Milwaukee, WI. Dr. Earing serves on the ACHA Medical Advisory Board.

About the Adult Congenital Heart Association
The mission of the Adult Congenital Heart Association (ACHA) is to improve and extend the lives of the millions born with heart defects through education, advocacy and the promotion of research. If you would like to find out more about our programming, visit our website, www.achaheart.org. To support ACHA’s mission to improve and prolong the lives of heart defect survivors, you can make a donation on our website.

This webinar was made possible in part by unrestricted educational grants from Actelion Pharmaceuticals US, Inc., Gilead Sciences, and St. Jude Medical Foundation.